# US 6,727,263 B2 · Indole and 2,3-dihydroindole derivatives, their preparation and use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,263 B2
- Document ID: US6727263B2
- Status: Granted
- Kind: B2
- Application number: 10/223,046
- Filed: 2002-08-16
- Published: 2003-01-23
- Granted: 2004-04-27
- Earliest claimed: 1997-07-25
- Assignees: H. Lundbeck A/S
- Inventors: Ejner Knud Moltzen; Jens Kristian Perregaard; Ivan Mikkelsen; Garrick Paul Smith
- Web page: https://patentgrep.com/patent/US6727263B2

## CPC

- C07D 405/12: linked by a chain containing hetero atoms as chain links
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/24: Antidepressants
- C07D 405/14: containing three or more hetero rings
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to indole and 2,3-dihydroindole derivatives having formula (I) or any of its any of its enantiometers or any mixture thereof, or an acid addition salt thereof, wherein A, R1, R2, R3, W, X, Y and Z are as described in the description. The compounds are potent serotonin reuptake inhibitors and have 5-HT1A receptor antagonistic activity.

## Claims

### Claim 1

An indole or 2,3-dihydro-indole derivative of the formula:
any of its enantiomers or any mixture thereof, or an acid addition salt thereof, wherein
X is —O— or —S—, or —CR4R5—; and
Y is —CR6R7—,—CR6R7—CR8R9—, or —CR6═CR7—; or
X and Y together form a group —CR4═CR5—, or —CR4═CR5—CR6R7—;
Z is —O— or —S—;
A is selected from a group of formula (II) and (IV)
wherein the dotted lines mean an optional bond;
R1, R2, R3, R12, R13, R14, R15, R16 and R17 are each independently selected from hydrogen, halogen, trifluoromethyl, alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, hydroxy, formyl, acyl, amino, alkylamino, dialkylamino, acylamino, alkoxycarbonylamino, aminocarbonylamino, alkylaminocarbonylamino, dialkylaminocarbonylamino, nitro and cyano;
R4, R5, R6, R7, R8 and R9 are each independently selected from hydrogen and alkyl; and
R11 is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, phenyl, naphthyl, phenylalkyl, acyl and formyl.

### Claim 2 (depends on 1)

The compounds of claim 1 wherein Z is —O—.

### Claim 3 (depends on 1)

The compounds of claim 1 wherein Z is —S—.

### Claim 4 (depends on 1)

The compounds of claim 1 wherein A is a group of formula (II).

### Claim 5 (depends on 1)

The compounds of claim 1 wherein A is a group of formula (IV).

### Claim 6 (depends on 2)

The compounds of claim 2 wherein A is a group of formula (II).

### Claim 7 (depends on 2)

The compounds of claim 2 wherein A is a group of formula (IV).

### Claim 8 (depends on 3)

The compounds of claim 3 wherein A is a group of formula (II).

### Claim 9 (depends on 3)

The compounds of claim 3 wherein A is a group of formula (IV).

### Claim 10 (depends on 1)

The compounds of claim 1 wherein R4, R5, R6, R7, R8 and R9 are selected from hydrogen or methyl.

### Claim 11 (depends on 1)

The compounds of claim 1 selected from the group consisting of
6-Chloro-3-[2-[4-(2,2,5-trimethyl-2,3-dihydrobenzofuran-7-yl)piperidin-1-yl]ethyl]-1H-indole;
6-Chloro-3-[2-[4-(2,2,-dimethyl-2,3-dihydrobenzofuran-7-yl)piperidin-1-yl]ethyl]-1H-indole;
6-Chloro-3-[2-[4-(2,2,-dimethyl-2,3-dihydrobenzofuran-7-yl)-1,2,3,6-tetrahydro-1-pyridy]ethyl]-1H-indole;
3-[2-[4-(1,4-Benzodioxan-5-yl)-1,2,3,6-tetrahydropyridin-1-yl]ethyl]-5-chloro-1H-indole;
3-[2-[4-(1,4-Benzodioxan-5-yl)-1,2,3,6-tetrahydropyridin-1-yl]ethyl]-5-fluoro-1H-indole;
3-[2-[4-(1,4-Benzodioxan-5-yl)piperidin-1-yl]ethyl]-6-chloro-1H-indole;
3-[2-[4-(1,4-Benzodioxan-5-yl)piperidin-1-yl]ethyl]-5-chloro-1H-indole;
3-[2-[4-(1,4-Benzodioxan-5-yl)piperidin-1-yl]ethyl]-5-fluoro-1H-indole;
6-Chloro-3-[2-[4-(2,3-dihydrobenzofuran-7-yl)-1,2,3,6-tetrahydropyridin-1-yl]ethyl]-1H-indole;
3-[2-[4-(Benzofuran-7-yl-1,2,3,6-tetrahydropyridin-1-yl]ethyl]-6-chloro-1H-indole;
3-[2-[4-(Benzofuran-7-yl-1,2,3,6-tetrahydropyridin-1-yl]ethyl]-5-bromo-1H-indole;
3-[2-[4-(Benzofuran-7-yl-1,2,3,6-tetrahydropyridin-1-yl]ethyl]-5-fluoro-1H-indole;
3-[2-[4-(Benzofuran-7-yl)piperidin-1-yl]ethyl]-6-chloro-1H-indole;
3-[2-[4-(Benzofuran-7-yl)piperidin-1-yl]ethyl]-5-fluoro-1H-indole;
3-[2-[4-(1,4-Benzodioxan-5-yl)-1,2,3,6-tetrahydro-1-pyridyl]ethyl]-6-chloro-1H-indole:
3-[2-[4-(1,4-Benzodioxan-5-yl)-piperidin-1-yl]ethyl]-6-chloro-1H-indole; and
3-[2-[4-(Benzofuran-7-yl)piperidin-1-yl]ethyl]-5-bromo-1H-indole;
or an acid addition salt thereof.

### Claim 12 (depends on 1)

A method of treating a disorder or disease of a living animal body, said disorder or disease selected from the group consisting of an affective disorder, anxiety disorder, panic disorder and obsessive compulsive disorder, comprising administering to said living animal body a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable acid addition salt thereof.

### Claim 13

An indole or 2,3-dihydro-indole derivative of the formula:
any of its enantiomers or any mixture thereof, or an acid addition salt thereof, wherein
X is —O— or —S—, or —CR4R5—; and
Y is —CR6R7—CR8R9—, or —CR6═CR7—; or
X and Y together toxin a group —CR4═CR5—, or —R4═CR5—CR6R7—;
Z is —O— or —S—;
provided that when X and Z are both O, then Y is —CR6R7—CR8R9— or CR6═CR7—;
A is selected from a group of formula (II), (III) and (IV)
wherein the dotted lines mean an optional bond;
R1, R2, R3, R12, R13, R14, R15, R16 and R17 are each independently selected from hydrogen, halogen, trifluoromethyl, alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, hydroxy, formyl, acyl, amino, alkylamino, dialkylamino, acylamino, alkoxycarbonylamino, aminocarbonylamino, alkylaminocarbonylamino, dialkylaminocarbonylamino, nitro and cyano;
R4, R5, R6, R7, R8 and R9 are each independently selected from hydrogen and alkyl; and
R11 is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, phenyl, naphthyl, phenylalkyl, acyl and formyl.

### Claim 14 (depends on 13)

The compounds of claim 13 wherein Z is —O—.

### Claim 15 (depends on 13)

The compounds of claim 13 wherein Z is —S—.

### Claim 16 (depends on 13)

The compounds of claim 13 wherein A is a group of formula (II).

### Claim 17 (depends on 13)

The compounds of claim 13 wherein A is a group of formula (III).

### Claim 18 (depends on 13)

The compounds of claim 13 wherein A is a group of formula (IV).

### Claim 19 (depends on 14)

The compounds of claim 14 wherein A is a group of formula (II).

### Claim 20 (depends on 14)

The compounds of claim 14 wherein A is a group of formula (III).

### Claim 21 (depends on 14)

The compounds of claim 14 wherein A is a group of formula (IV).

### Claim 22 (depends on 15)

The compounds of claim 15 wherein A is a group of formula (II).

### Claim 23 (depends on 15)

The compounds of claim 15 wherein A is a group of formula (III).

### Claim 24 (depends on 15)

The compounds of claim 15 wherein A is a group of formula (IV).

### Claim 25 (depends on 13)

The compounds of claim 13 wherein R4, R5, R6, R7, R8 and R9 are selected from hydrogen or methyl.

### Claim 26 (depends on 13)

A method of treating a disorder or disease of a living animal body, said disorder or disease selected from the group consisting of an affective disorder, an anxiety disorder, panic disorder and obsessive compulsive disorder, comprising administering to said living animal body a therapeutically effective amount of a compound of claim 13, or a pharmaceutically acceptable acid addition salt thereof.
